Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PfSPZ-LARC2 Vaccine in Healthy African Adult Women of Childbearing Potential in Mali
NCT07675785Phase 2Recruiting
- Sponsor
- Sanaria Inc.
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PfSPZ-LARC2 in malaria (2 arms), sponsored by Sanaria Inc. Primary endpoints: Incidence of local adverse events, Incidence of systemic adverse events and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
PfSPZ-LARC2
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07675785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07675785.